KINDRED BIOSCIENCES, INC. (NASDAQ:KIN) Files An 8-K Other Events

KINDRED BIOSCIENCES, INC. (NASDAQ:KIN) Files An 8-K Other Events
Item 8.01Other Events.

Story continues below

On January 14, 2019, Kindred Biosciences, Inc. issued a press release announcing positive topline results from its pilot field effectiveness study of epoCat™ for the management of non-regenerative anemia in cats and the availability of Mirataz® at Banfield Pet Hospital. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01Financial Statements and Exhibits.

(d)Exhibits

Kindred Biosciences, Inc. Exhibit
EX-99.1 2 pressreleasejanuary142019.htm EXHIBIT 99.1 JANUARY 14,…
To view the full exhibit click here

About KINDRED BIOSCIENCES, INC. (NASDAQ:KIN)

Kindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company’s lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The Company’s other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis.

An ad to help with our costs